DNTH compared with CGON: revenue, margins and what each company keeps, and the suppliers and customers both name

DNTHDianthus Therapeutics, Inc.

Mkt capRevenueRevenue

CGONCG Oncology, Inc.

Mkt capRevenueRevenue

Compare

DNTHDianthus Therapeutics, Inc.

CGONCG Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

DNTH: latest quarter is a loss; flow not drawable. CGON: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only DNTH 3

—Nanjing Leads Biolabsunlistedsupplier

—IONTASunlistedsupplier

—Tenacia Biotechnology (Hong Kong)unlistedcustomer

Shared 0

No disclosed counterparties: CGON.

Only CGON 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

DNTH, solidCGON, dashed

DNTHDianthus Therapeutics, Inc.

82.00▼−0.85%· post 82.00

Mkt cap$4.6BRevenue$761,000Q2 FY26Revenue$6MFY24

CGONCG Oncology, Inc.

64.58▲+1.75%· post 64.65

ClosedOct 30 '26

Mkt cap$5.7BRevenue$1MQ2 FY26Revenue—

Compare

ClosedOct 30 '26

DNTHDianthus Therapeutics, Inc.

CGONCG Oncology, Inc.

82.00▼−0.85%post 82.00

Price

64.58▲+1.75%post 64.65

$4.6B

Mkt cap

$5.7B

Q2 FY26$761,000

Revenue

$1MQ2 FY26

FY24$6M

Revenue

—

DNTH82.00▼−0.85%vsCGON64.58▲+1.75%ClosedOct 30 '26